Drugs / TDF-FTC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03826199 | Aug 2019 → Dec 2021 | HIV infectious disease | University of California, Los Angeles | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TDF-FTC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03826199 ↗ |
| Known as | Tenofovir/Emtricitabine | “pregnant AGYW (age: 16-25 years) who initiated daily oral PrEP (Tenofovir/Emtricitabine) antenatally” PMID 36947792 ↗ Mar 2023 |
| Route | Oral | “pregnant AGYW (age: 16-25 years) who initiated daily oral PrEP (Tenofovir/Emtricitabine) antenatally” PMID 36947792 ↗ Mar 2023 |